Harmeet Sidhu
Profile
Harmeet Sidhu served as President & Chief Operating Officer at Ixion Biotechnology, Inc. and as Chief Scientific Officer at OxThera AB.
Sidhu holds a doctorate degree from the Post Graduate Institute of Medical Education & Research.
Former positions of Harmeet Sidhu
Companies | Position | End |
---|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Chief Tech/Sci/R&D Officer | - |
Ixion Biotechnology, Inc.
Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | President | - |
Training of Harmeet Sidhu
Post Graduate Institute of Medical Education & Research | Doctorate Degree |
Experiences
Positions held
Linked companies
Private companies | 2 |
---|---|
Ixion Biotechnology, Inc.
Ixion Biotechnology, Inc. BiotechnologyHealth Technology Ixion Biotechnology, Inc. develops somatic cellular therapies to treat diabetes. The company was founded by Weaver H. Gaines and David C. Peck on April 4, 1994 and is headquartered in Alachua, FL. | Health Technology |
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
- Stock Market
- Insiders
- Harmeet Sidhu